MariMed (MariMed) Change In Receivables : $-2.3 Mil (TTM As of Mar. 2024)

View and export this data going back to 2012. Start your Free Trial

What is MariMed Change In Receivables?

MariMed's change in receivables for the quarter that ended in Mar. 2024 was $0.7 Mil. It means MariMed's Accounts Receivable declined by $0.7 Mil from Dec. 2023 to Mar. 2024 .

MariMed's change in receivables for the fiscal year that ended in Dec. 2023 was $-3.2 Mil. It means MariMed's Accounts Receivable increased by $3.2 Mil from Dec. 2022 to Dec. 2023 .

MariMed's Accounts Receivable for the quarter that ended in Mar. 2024 was $6.5 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. MariMed's Days Sales Outstanding for the three months ended in Mar. 2024 was 15.61.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. MariMed's liquidation value for the three months ended in Mar. 2024 was $-97.9 Mil.

MariMed Change In Receivables Historical Data

The historical data trend for MariMed's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MariMed Change In Receivables Chart

MariMed Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-36.35

-5.98

-4.70

-6.90

-3.16

MariMed Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-0.13	-1.32	-0.62	-1.10	0.71

MariMed Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.3 Mil.

MariMed (OTCPK:MRMD) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

MariMed's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	6.491	/	37.933	*	91
=	15.61

2. In Ben Graham's calculation of liquidation value, MariMed's accounts receivable are only considered to be worth 75% of book value:

MariMed's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	15.234	-	132.511	+	0.75 * 6.491	+	0.5 * 29.044
=	-97.9

MariMed Change In Receivables Related Terms

Thank you for viewing the detailed overview of MariMed's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

MariMed (MariMed) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » MariMed Inc (OTCPK:MRMD) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

MRMD:Canada

Address

10 Oceana Way, Floor 2, Norwood, MA, USA, 02062

Website

https://www.marimedinc.com

MariMed Inc is a multi-state operator in the United States cannabis industry. It develops, operates, manages, and optimizes regulatory-compliant facilities for the cultivation, production, and dispensing of medical and adult-use cannabis. MariMed also licenses its proprietary brands of cannabis products along with other top brands in domestic markets Sources of revenue are comprised of Product sales (retail and wholesale), Real estate rental income, Supply procurement, Management fees, and Licensing fees.

Executives

Jon R Levine	10 percent owner	C/O MARIMED INC., 10 OCEANA WAY, NORWOOD MA 02062
Timothy Shaw	officer: Chief Operating Officer	C/O MARIMED INC, 10 OCEANA WAY, NORWOOD MA 02062
Kathleen Tucker	director	C/O 10 OCEANA WAY, 2ND FLOOR, NORWOOD MA 02062
Susan M. Villare	officer: Chief Financial Officer	C/O MARIMED INC., 10 OCEANA WAY, NORWOOD MA 02062
Selhub Eva M.d.	director	C/O MARIMED INC., 10 OCEANA WAY, NORWOOD MA 02062
David R Allen	director	C/O CONVERTED ORGANICS INC., 7A COMMERCIAL WHARF WEST, BOSTON MA 02110
Thomas Kidrin	director	11 ROYAL ROAD, BROOKLINE MA 02445
Edward J Gildea	director	C/O CONVERTED ORGANICS INC., 7A COMMERCIAL WHARF WEST, BOSTON MA 02110
Jay Coleman	director	310 EAST 46TH ST. APT 9 F, NEW YORK NY 10017
Robert N Fireman	director	145 ROSEMARY ST. SUITE H-2, NEEDHAM MA 02494
Worlds.com, Inc.	director, 10 percent owner, officer: PRESIDENT, CEO, other: TREASURER, SECRETARY	11 ROYAL ROAD, BROOKLINE MA 02445
Christopher John Ryan	officer: CFO, VICE PRESIDENT	11 ROYAL RD, BROOKLINE MA 02445